CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CCT-251921
CAS:<p>CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).</p>Fórmula:C21H23ClN6OPureza:99.07%Cor e Forma:SolidPeso molecular:410.9CDK9-IN-8
CAS:<p>CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).</p>Fórmula:C31H32FN7O3Pureza:99.54%Cor e Forma:SolidPeso molecular:569.63QR-6401
CAS:<p>QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/</p>Fórmula:C19H23N5O3Pureza:98%Cor e Forma:SolidPeso molecular:369.42Tacaciclib
CAS:<p>Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].</p>Fórmula:C30H36N6O3Pureza:98%Cor e Forma:SolidPeso molecular:528.65Mevociclib
CAS:<p>Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.</p>Fórmula:C31H35ClN8O2Pureza:98.02% - 98.02%Cor e Forma:SolidPeso molecular:587.11Palbociclib orotate
CAS:<p>Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.</p>Fórmula:C29H33N9O6Pureza:98%Cor e Forma:SolidPeso molecular:603.63KM05382
CAS:<p>KM05382 inhibits CDK9 and the transcription of GAPDH.</p>Fórmula:C20H19ClN2O3S2Cor e Forma:SolidPeso molecular:434.96CDK4-IN-2
CAS:<p>CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].</p>Fórmula:C22H26F2N6O4SPureza:98%Cor e Forma:SolidPeso molecular:508.54DCB-3503
CAS:<p>DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.</p>Fórmula:C24H27NO5Cor e Forma:SolidPeso molecular:409.47LDC3140
CAS:<p>LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).</p>Fórmula:C23H33N7OPureza:98%Cor e Forma:SolidPeso molecular:423.55Leucettinib-92
CAS:<p>Leucettinib-92 (compound 92) is a kinase inhibitor selective for DYRK/CLK families, displaying IC50 values of 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM</p>Fórmula:C21H22N4OSPureza:98%Cor e Forma:SolidPeso molecular:378.49CDK9-IN-9
CAS:<p>CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).</p>Fórmula:C22H23F2N5O2SPureza:98%Cor e Forma:SolidPeso molecular:459.51(2S,3R)-Voruciclib
CAS:<p>(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.</p>Fórmula:C22H19ClF3NO5Pureza:98%Cor e Forma:SolidPeso molecular:469.84CDK9-IN-2
CAS:<p>CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.</p>Fórmula:C23H25ClFN5Pureza:99%Cor e Forma:SolidPeso molecular:425.93CDK7-IN-14
CAS:<p>CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).</p>Fórmula:C22H24F3N6OPCor e Forma:SolidPeso molecular:476.435-Iodo-indirubin-3'-monoxime
CAS:<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Fórmula:C16H10IN3O2Cor e Forma:SolidPeso molecular:403.17NU6300
CAS:<p>NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.</p>Fórmula:C20H23N5O3SPureza:96.08%Cor e Forma:SolidPeso molecular:413.49Voruciclib hydrochloride
CAS:<p>Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).</p>Fórmula:C22H20Cl2F3NO5Pureza:98%Cor e Forma:SolidPeso molecular:506.3PF-6808472
CAS:<p>PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.</p>Fórmula:C25H27FN8O3SPureza:99.02%Cor e Forma:SolidPeso molecular:538.6CDK7-IN-22
CAS:<p>CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].</p>Fórmula:C22H25F3N6Pureza:98%Cor e Forma:SolidPeso molecular:430.47
